Amgen snaps up UK biotech Dark Blue Therapeutics in up to $840m oncology deal
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
Subscribe To Our Newsletter & Stay Updated